Literature DB >> 10529724

Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.

Y Itzhak1, J L Martin, S F Ali.   

Abstract

Previous studies have suggested a role for the retrograde messenger, nitric oxide (NO), in methamphetamine (METH)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced dopaminergic neurotoxicity. Since evidence supported the involvement of the neuronal nitric oxide synthase (nNOS) isoform in the dopaminergic neurotoxicity, the present study was undertaken to investigate whether the inducible nitric oxide synthase (iNOS) isoform is also associated with METH- and MPTP-induced neurotoxicity. The administration of METH (5mg/kg x 3) to iNOS deficient mice [homozygote iNOS(-/-)] and wild type mice (C57BL/6) resulted in significantly smaller depletion of striatal dopaminergic markers in the iNOS(-/-) mice compared with the wild-type mice. METH-induced hyperthermia was also significantly lower in the iNOS(-/-) mice than in wild-type mice. In contrast to the outcome of METH administration, MPTP injections (20 mg/kg x 3) resulted in a similar decrease in striatal dopaminergic markers in iNOS(-/-) and wild-type mice. In the set of behavioral experiments, METH-induced locomotor sensitization was investigated. The acute administration of METH (1.0 mg/kg) resulted in the same intensity of locomotor activity in iNOS(-/-) and wild-type mice. Moreover, 68 to 72 h after the exposure to the high-dose METH regimen (5 mg/kg x 3), a marked sensitized response to a challenge injection of METH (1.0 mg/kg) was observed in both the iNOS(-/-) and wild-type mice. The finding that iNOS(-/-) mice were unprotected from MPTP-induced neurotoxicity suggests that the partial protection against METH-induced neurotoxicity observed was primarily associated with the diminished hyperthermic effect of METH seen in the iNOS(-/-) mice. Moreover, in contrast to nNOS deficiency, iNOS deficiency did not affect METH-induced behavioral sensitization. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529724     DOI: 10.1002/(SICI)1098-2396(19991215)34:4<305::AID-SYN6>3.0.CO;2-#

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  17 in total

Review 1.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

2.  Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity.

Authors:  Danielle M Friend; Jong H Son; Kristen A Keefe; Ashley N Fricks-Gleason
Journal:  J Pharmacol Exp Ther       Date:  2012-12-10       Impact factor: 4.030

3.  CD200 attenuates methamphetamine-induced microglial activation and dopamine depletion.

Authors:  Xia Yue; Dongfang Qiao; Aifeng Wang; Xiaohui Tan; Yanhong Li; Chao Liu; Huijun Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

Review 4.  Oxidative and nitrative stress in neurodegeneration.

Authors:  Catherine A Cobb; Marsha P Cole
Journal:  Neurobiol Dis       Date:  2015-05-27       Impact factor: 5.996

5.  Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.

Authors:  Rebecca Banerjee; Karuppagounder S Saravanan; Bobby Thomas; Kizhake M Sindhu; Kochupurackal P Mohanakumar
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 6.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

7.  Chronic wheel running reduces maladaptive patterns of methamphetamine intake: regulation by attenuation of methamphetamine-induced neuronal nitric oxide synthase.

Authors:  Alexander J Engelmann; Mark B Aparicio; Airee Kim; Jeffery C Sobieraj; Clara J Yuan; Yanabel Grant; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2013-02-27       Impact factor: 3.270

8.  Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.

Authors:  Yu Watanabe; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2007-11-21       Impact factor: 3.584

9.  Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease.

Authors:  L Hunter Randy; Bing Guoying
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

Review 10.  Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?

Authors:  Danielle M Friend; Ashley N Fricks-Gleason; Kristen A Keefe
Journal:  Neurotox Res       Date:  2013-08-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.